Bioenergy Life Science adopts decentralised clinical research to support nutraceutical claims

Methodological Shift and Pilot Design

The core proposition from Bioenergy Life Science (BLS) is the replacement of traditional site-based Contract Research Organisation (CRO) studies with remote, real-world trials. Their recent 30-day pilot evaluating a 750 mg dose of their RiaGev-WS ingredient—an NAD+-boosting compound—exemplifies this model. Conducted with Vermont Food Science, the study involved participants aged 40-59 maintaining normal daily routines without dietary restrictions, aiming to generate data under conditions that more closely mirror actual consumer use patterns.

The trial structure incorporated a proprietary dried blood spot assay, a critical technical adaptation for decentralised studies. Traditional NAD+ quantification from whole blood requires rapid sample stabilisation—a logistical barrier for remote collection. This modified assay allowed participants to self-collect samples at home, which were then sent for centralised analysis, theoretically enabling more frequent and practical biomarker tracking.

Reported Outcomes and Analytical Limitations

The pilot reported an 83% adherence rate to the dosing protocol and an 85% overall product satisfaction rate. Crucially, the company states no adverse events were reported during the trial period. For a 30-day intervention in a healthy demographic, this safety signal is preliminary but positive.

The most cited biochemical finding is an approximately 20% increase in NAD+ levels measured via the dried blood spot assay after 20 days. While this figure is promoted, several analytical questions arise. The precision and validation status of the proprietary assay versus established laboratory methods are not detailed in the available data. Furthermore, self-reported improvements in subjective parameters like energy, mood, and mental clarity are subject to substantial placebo effect and expectation bias, particularly in an unblinded, real-world setting where participants were aware of the product being tested. The company has announced plans for a larger, 100-participant study over eight weeks, incorporating an additional active ingredient in a practitioner-focused formulation.

Implications for the Nutraceutical Evidence Ecosystem

From a clinical nutrition perspective, this decentralised model’s primary appeal is economic. It promises to lower the barrier to generating finished-product-specific data, a requirement underscored by the FTC’s 2022 guidance mandating evidence that directly supports the marketed product. For ingredient suppliers like BLS, this serves as a differentiator: offering brand partners not just a raw material, but a turnkey, gold-standard protocol (double-blind, placebo-controlled is claimed) for their own product validation.

However, the scientific robustness of such data requires scrutiny. Real-world trials trade environmental control for ecological validity, introducing higher variability. The lack of stringent dietary or activity controls, while reflective of actual use, complicates the isolation of the ingredient’s effect from confounding lifestyle factors. For the practitioner and scientifically literate consumer, the critical takeaway is to examine the full protocol and statistical analysis of any such study, not just the headline satisfaction metrics or single biomarker percentages. The industry trend toward cost-effective claim substantiation must be balanced against the established hierarchy of evidence, where randomised, controlled trials in controlled settings remain the benchmark for causal inference.